Their groundbreaking study identified aberrant methylation of the ARD1 promoter in non‐small cell lung cancer (NSCLC), suggesting ARD1 as a potential prognostic biomarker [32]. The gene discussed is NAA10; the disease is non-small cell lung carcinoma.